# Humana Inc. (HUM) stock news and updates

As of November 16, 2026. Source: https://www.clearthesis.ai/updates/HUM

## Our view on the Humana Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/HUM

## Latest updates on Humana Inc.

### Humana removes prior authorization for certain cancer care services

*November 11, 2026 · news · significance: notable · signal: positive*

Humana is launching a new model for cancer care that removes the need for prior authorization, the process where doctors must get an insurer's approval before starting a treatment. By working with Evolent and the American Oncology Network, the company is allowing doctors to follow pre-approved clinical paths instead of waiting for individual case reviews. This is a smart move to lower the administrative costs that often frustrate both doctors and patients. For a long-term owner, it shows Humana is finding ways to make its insurance plans more attractive and efficient without sacrificing care quality. Reducing these hurdles can lead to better health outcomes and lower long-term costs by getting patients into the right treatments faster.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261110782087/en/New-oncology-model-from-Humana-Evolent-and-American-Oncology-Network-eliminates-prior-authorization-burden/)

### Humana offers to buy back some of its outstanding debt

*November 9, 2026 · news · significance: minor · signal: neutral*

Humana has started a process to buy back several of its outstanding notes, which are essentially IOUs the company issued to borrow money. By offering to pay cash for these debts now, the company can reduce its future interest payments and manage its balance sheet more effectively. This is a routine financial move for a company of this size. It suggests Humana has enough cash on hand to comfortably settle these obligations early, but it does not change the core outlook for its insurance or clinical businesses.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261108416908/en/Humana-Commences-Offers-to-Purchase-for-Cash-Certain-of-its-Outstanding-Debt-Securities/)

### We updated our thesis on Humana

*November 7, 2026 · news · significance: notable · signal: neutral*

After Humana reported its November results, we updated our fair value and raised our quality score to 3.7. We now rate management and the handling of the company’s biggest risks more highly. We raised our profit expectations for the year to $9.50 per share and added the new joint venture with BlackRock to what we track. We also adjusted our medical cost projections to account for the insurance division spending 93.7% of its premium revenue on care.

### Humana raised its full-year profit outlook as medical costs came in lower than expected

*November 6, 2026 · earnings · significance: major · signal: positive*

Humana reported a loss of $0.70 per share for the third quarter, which was better than the $1.00 loss analysts expected. While the company is losing money this quarter, it is a planned dip as it spends heavily to sign up new members. Revenue reached $41.16 billion, slightly ahead of expectations. The most important detail for investors is the benefit ratio, which measures how much of every premium dollar the company pays out for medical care. That ratio was 93.7 percent, better than management's own forecast. This suggests that the spike in medical costs that has hit the insurance industry lately is starting to stabilize. Because of this, Humana raised its full-year profit goal to at least $9.50 per share, up from its previous target of $9.00. Its CenterWell business, which runs primary care clinics and pharmacies, also grew its patient count by 30 percent this year. This is a key part of the company's long-term plan to control costs by treating patients in its own facilities rather than just paying outside hospital bills.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/49071/000004907126000064/0000049071-26-000064-index.htm)

### Humana expands digital tools to speed up care approvals

*November 3, 2026 · news · significance: minor · signal: positive*

Humana is expanding its digital link with athenahealth to handle prior authorizations, which are the approvals doctors must get from insurers before certain treatments. By moving this process into the software physicians already use, the company aims to cut down on paperwork and help patients get care faster. This is a small but useful step in Humana's broader plan to lower its own administrative costs. Making it easier for doctors to work with the insurer can also help keep them in Humana's network, which is important for keeping its 6 million members satisfied.

Sources: [Business Wire](https://www.businesswire.com/news/home/20261103468691/en/Humana-and-athenahealth-expand-electronic-prior-authorization-capabilities-nationwide-reducing-administrative-burden-for-physicians-and-helping-patients-access-care-faster/)

## Humana Inc. earnings

In Q3 2026, reported on November 6, 2026, Humana Inc. posted earnings of $-0.70 per share against $-1.00 expected, and revenue of $41.2 billion against $40.9 billion expected.

The next earnings report is expected on February 10, 2027. Analysts expect $-7.60 per share. Revenue is expected around $41.3 billion.

What to watch: Whether the share of members in high-rated plans recovers, as these quality scores decide how much bonus money the government pays the company.

## Recent analyst activity on HUM

- November 12, 2026: Wells Fargo Kept rating at Overweight.
- November 11, 2026: TD Cowen Kept rating at Hold.
- November 10, 2026: JP Morgan Kept rating at Neutral.
- November 9, 2026: Barclays Kept rating at Overweight.
- November 9, 2026: Piper Sandler Kept rating at Overweight, set target. Price target: $526.00.
- November 9, 2026: Cantor Fitzgerald Kept rating at Overweight.

## What's ahead for Humana Inc.

- December 24, 2026: Dividend payday — Own the stock before this date to get the next dividend payment.
- February 10, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/HUM
